| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3291865 | Gastroenterology | 2016 | 10 Pages |
Abstract
In cirrhotic HCV GT1- or GT3-infected patients, ABT-493 plus ABT-530 with or without RBV achieved SVR12 rates of 96%-100% and was well tolerated. ClinicalTrials.gov identifiers NCT02243280 and NCT02243293.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Edward Gane, Fred Poordad, Stanley Wang, Armen Asatryan, Paul Y. Kwo, Jacob Lalezari, David L. Wyles, Tarek Hassanein, Humberto Aguilar, Benedict Maliakkal, Ran Liu, Chih-Wei Lin, Teresa I. Ng, Jens Kort, Federico J. Mensa,